RT Journal Article
SR Electronic
T1 2020 SARS-CoV-2 diversification in the United States: Establishing a pre-vaccination baseline
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.01.21258185
DO 10.1101/2021.06.01.21258185
A1 Capoferri, Adam A.
A1 Shao, Wei
A1 Spindler, Jon
A1 Coffin, John M.
A1 Rausch, Jason W.
A1 Kearney, Mary F.
YR 2021
UL http://medrxiv.org/content/early/2021/06/04/2021.06.01.21258185.abstract
AB In 2020, SARS-CoV-2 spread across the United States (U.S.) in three phases distinguished by peaks in the numbers of infections and shifting geographical distribution. We investigated the viral genetic diversity in each phase using sequences publicly available prior to December 15th, 2020, when vaccination was initiated in the U.S. In Phase 1 (winter/spring), sequences were already dominated by the D614G Spike mutation and by Phase 3 (fall), genetic diversity of the viral population had tripled and at least 54 new amino acid changes had emerged at frequencies above 5%, several of which were within known antibody epitopes. These findings highlight the need to track the evolution of SARS-CoV-2 variants in the U.S. to ensure continued efficacy of vaccines and antiviral treatments.One Sentence Summary SARS-CoV-2 genetic diversity in the U.S. increased 3-fold in 2020 and 54 emergent nonsynonymous mutations were detected.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this research was provided by the National Cancer Institute Intramural Center for Cancer Research which supports the HIV Dynamics and Replication Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was necessary as the sequences were obtained from a public database. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services of the Unites States government.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the main text or the supplementary materials. In addition, can be accessed on GISAID.org.